Aside from ZYESAMI... there is BriLife... and perhaps just in time.
Interesting how if you wait on initial news reports.. you learn so much more! This new variant sounds a bit worrisome... except that it appears so far that it may not be as severe.. at least for the healthy.
The difference between the first US "Man Engineered" vaccine and BriLife being studied by NRXP is interesting in that BriLife seems to be manufactured by traditional means and contains all the genetic material so that our bodies can recognize any possible variant. It appears.. so far that the US man-made vaccines are limited in scope with regards to preparing our body's immune system to recognize variants.
From and earlier News Release:
"BriLife presents the entire spike protein complex of the coronavirus to the body's immune system and can simultaneously present multiple variants of the spike protein."
Most reported U.S. Omicron cases have hit the fully vaccinated -CDC
By Mrinalika Roy Dec 10 (Reuters) -
Most of the 43 COVID-19 cases caused by the Omicron variant identified in the United States so far were in people who were fully vaccinated, and a third of them had received a booster dose, according to a U.S. report published on Friday.
The U.S. Centers for Disease Control and Prevention (CDC) said that of the 43 cases attributed to Omicron variant, 34 people had been fully vaccinated. Fourteen of them had also received a booster, although five of those cases occurred less than 14 days after the additional shot before full protection kicks in.
While the numbers are very small, they add to growing concerns that current COVID-19 vaccines may offer less protection against the highly transmissible new variant.
The Omicron variant of the coronavirus has been found through testing in about 22 states so far after first being identified in southern Africa and Hong Kong in late November.
Among the Omicron cases, 25 were in people aged 18 to 39 and 14 had traveled internationally. Six people had previously been infected with the coronavirus.
Most of them only had mild symptoms such as coughing, congestion, and fatigue, the report said, and one person was hospitalized for two days. Other symptoms reported less frequently including nausea or vomiting, shortness of breath or difficulty breathing, diarrhea and loss of taste or smell.
The CDC said that while many of the first reported Omicron cases appear to be mild, a lag exists between infection and more severe outcomes. Symptoms would also be expected to be milder in vaccinated persons and those with previous SARS-CoV-2 infection.
The first known U.S. Omicron case was identified on Dec 1 in a fully vaccinated person who had traveled to South Africa. The CDC said that the earliest date of symptom onset was Nov. 15 in a person with a history of international travel.
The Delta variant still accounts for more than 99% of all U.S. cases. But reports from South Africa show that the Omicron variant is very transmissible.
Even if most cases are mild, a highly transmissible variant could result in enough infections to overwhelm health systems, the CDC cautioned.
Laboratory studies released this week suggest that the Omicron variant will blunt the protective power of two doses of Pfizer (PFE.N) and BioNTech's COVID-19 vaccine, although a third dose may restore that protection.
The U.S. has authorized COVID-19 vaccine boosterdoses for all Americans age 16 and older.
Market Data 
Markets 
AI
